| Primary information |
|---|
| sequence ID | Seq_8321 |
| Peptide sequence | TKSPLFMGKVVNPTQK |
| CancerPDF_ID | CancerPDF_ID9506, CancerPDF_ID9507, |
| PMID | 21533267,21533267 |
| Protein Name | Alpha-1-antitrypsin,Alpha-1-antitrypsin |
| UniprotKB Entry Name | A1AT_HUMAN,A1AT_HUMAN |
| Fluid | Serum,Serum |
| M/Z | 592.32,597.65 |
| Charge | 3,3 |
| Mass (in Da) | NA,NA |
| fdr | NA,NA |
| Profiling Technique | LC-MS,LC-MS |
| Peptide Identification technique | LC/MS/MS,LC/MS/MS |
| Quantification Technique | Multiple Reaction Monitoring,Multiple Reaction Monitoring |
| Labelled/Label Free | Label Free,Label Free |
| FDR | 1.49,1.49 |
| CancerPDF_ID | CancerPDF_ID9506, CancerPDF_ID9507, |
| p-Value | NA,NA |
| Software | MASCOT,MASCOT |
| Length | 16,16 |
| Cancer Type | Lung adenocarcinoma,Lung adenocarcinoma |
| Database | Swissprot Database (57.4),Swissprot Database (57.4) |
| Modification | NA,Oxidation |
| Number of Patients | 62 lung adenocarcinoma and 30 healthy control,62 lung adenocarcinoma and 30 healthy control |
| Regulation | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | MRM-based validation of 19 candidates,MRM-based validation of 19 candidates |
| Sensitivity | NA,NA |
| Specificity | NA,NA |
| Accuracy | NA,NA |
| Peptide Atlas | NA |
| IEDB | 439314
|